Frost Phillip MD ET AL, CEO and Chairman, has demonstrated a strong buying bias across two companies—Cocrystal Pharma (COCP) and OPKO Health (OPK)—with 83 total transactions amounting to $20.5 million in purchases and just $1.1 million in sales. The recent activity, spanning November 2025 to February 2026, shows an exclusively bullish stance, with 24 consecutive purchases and no sales. The largest transactions occurred in OPK, including a $281,890 acquisition on November 20, 2025, and a $261,558 purchase the day prior, part of a concentrated buying spree that saw over $1.8 million deployed in OPK shares across three days. Meanwhile, COCP saw steady but smaller purchases, including a $47,280 buy on February 6, 2026, and a $19,952 transaction on February 24, 2026. The pattern suggests a clear accumulation strategy, particularly in OPK, where Frost directed the majority of capital in late 2025 before shifting focus to smaller, more frequent COCP buys in early 2026. The absence of sales in the reported period reinforces a long-term holding approach, though the disparity in investment size between the two companies may reflect differing conviction levels or portfolio allocation strategies.
AI-assisted summary